Korea Investment CORP Cuts Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Korea Investment CORP reduced its Eli Lilly stake by 7.4% in the second quarter, selling 52,403 shares and retaining 658,950 shares valued at approximately $790.4 million. Institutional investors collectively own 82.53% of LLY.
• Eli Lilly exceeded quarterly expectations, reporting $8.38 in adjusted earnings per share versus the $6.40 consensus and revenue of $22.97 billion, up 47.7% year over year.
• Investor sentiment remains broadly positive but valuation and coverage risks persist: analysts maintain a “Moderate Buy” consensus with a $1,292.18 target, while concerns about GLP-1 drug reimbursement and Lilly’s elevated valuation could contribute to volatility.

Korea Investment CORP lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 658,950 shares of the company's stock after selling 52,403 shares during the quarter. Eli Lilly and Company comprises approximately 1.5% of Korea Investment CORP's holdings, making the stock its 12th largest holding. Korea Investment CORP owned 0.07% of Eli Lilly and Company worth $790,364,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in LLY. EP Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company by 19.1% in the second quarter. EP Wealth Advisors LLC now owns 96,123 shares of the company's stock worth $115,292,000 after purchasing an additional 15,393 shares during the last quarter. Burnham & Co LLC bought a new position in Eli Lilly and Company during the second quarter valued at approximately $9,736,000. Callan Family Office LLC grew its holdings in Eli Lilly and Company by 3.3% during the 2nd quarter. Callan Family Office LLC now owns 54,722 shares of the company's stock valued at $65,635,000 after buying an additional 1,768 shares in the last quarter. Manhattan West Asset Management LLC increased its stake in Eli Lilly and Company by 4.7% in the 2nd quarter. Manhattan West Asset Management LLC now owns 2,393 shares of the company's stock worth $2,870,000 after acquiring an additional 107 shares during the last quarter. Finally, Laidlaw Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 11.2% during the 2nd quarter. Laidlaw Wealth Management LLC now owns 1,052 shares of the company's stock worth $1,262,000 after acquiring an additional 106 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 1.2%

NYSE LLY opened at $1,175.01 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52 week low of $712.05 and a 52 week high of $1,292.65. The firm has a market capitalization of $1.11 trillion, a price-to-earnings ratio of 39.43, a PEG ratio of 1.40 and a beta of 0.51. The company has a fifty day moving average of $1,187.82 and a two-hundred day moving average of $1,064.57.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business's revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio is 23.22%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Zepbound real-world data: A study found that sustained Zepbound use among adults over 55 with overweight or obesity was associated with fewer hospital and emergency-room visits and lower healthcare costs. The findings could support broader payer acceptance and strengthen the case for Medicare coverage. Zepbound linked to lower healthcare costs
• Positive Sentiment: Alzheimer’s diagnostic milestone: The FDA cleared a blood test developed by Lilly and Roche to help identify Alzheimer’s-related amyloid pathology. A less-invasive test could expand access to diagnosis and support demand for Lilly’s Alzheimer’s franchise, including Kisunla. Eli Lilly clears hurdle in Alzheimer’s fight
• Positive Sentiment: Pipeline diversification: Oncology revenue increased 11% in the first half of 2026, while newer products and pipeline candidates may help Lilly reduce its dependence on GLP-1 medicines. Lilly also advanced brenipatide into a Phase 3 depression study, adding another potential long-term growth opportunity. Lilly oncology portfolio growth
• Neutral Sentiment: Valuation and positioning: Lilly remains near its 52-week high, and analysts’ median price target of approximately $1,348.50 implies additional upside. However, the elevated valuation leaves the stock vulnerable to sharp reactions when growth or reimbursement concerns emerge.
• Negative Sentiment: GLP-1 coverage concerns are weighing on sentiment: Employer-benefit surveys and reports that some companies may reduce coverage for weight-management drugs have renewed fears that payer restrictions could slow Zepbound and future oral obesity-drug adoption. The decline appears more sentiment-driven than a response to weaker operating results. GLP-1 coverage concerns
• Negative Sentiment: Cost-savings evidence has limitations: Lilly-sponsored research supports Zepbound’s medical and economic value, but critics note that the analysis measured healthcare savings before accounting for the drug’s price. This may weaken the immediate impact of the findings in payer negotiations. Lilly cost-saving study limitations

Insiders Place Their Bets

In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 over the last 90 days. Insiders own 0.14% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. UBS Group set a $1,376.00 target price on Eli Lilly and Company in a research report on Friday, August 7th. Guggenheim upped their price target on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a "buy" rating in a research note on Monday, July 13th. BMO Capital Markets reiterated an "outperform" rating and set a $1,400.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 6th. Morgan Stanley reissued an "overweight" rating and issued a $1,419.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Finally, Barclays upped their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a research report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $1,292.18.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source